Individualization of drug therapy: History, present state, and opportunities for the future

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 4, 2012, Pages 458-466

  Lesko, L J ^a   Schmidt, S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG CONTROL; DRUG EFFICACY; DRUG MONITORING; DRUG THERAPY; HUMAN; INDIVIDUALIZATION; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PHARMACOGENOMICS; PHARMACOKINETICS; PHYSIOLOGY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

DRUG MONITORING; FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 84866597034     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.113     Document Type: Article

References (53)

1. Wikipedia. Apothecary http://en.wikipedia.org/wiki/Apothecary.
2. Cowen, D.L. & Helfand, W.H. Pharmacy: An Illustrated History. (Mosby, Orlando, FL, 1990)
3. Bliss, M. The Discovery of Insulin (University of chicago Press, chicago, IL 1982).
4. Spear, B.B., Heath-Chiozzi, M. & Huf, J. clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001).
5. Reidenberg, M.M. Evolving ways that drug therapy is individualized. Clin. Pharmacol. Ther. 74, 197-202 (2003).
6. International Association of therapeutic Drug Monitoring and clinical toxicology. Defnition of tDM http://www.iatdmct.org/index.php/publisher/ articleview/frmArticleID/138/. Accessed 25 April 2012.
7. Lambert, J.S. et al. therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med. 12, 166-173 (2011).
8. Anonymous, Efective management of gout often requires multiple medications. Drug Ther. Perspect. 17, 8-12 (2001).
9. Hussaini, T., RüPing, M.J., Farowski, F., Vehreschild, J.J. & Cornely, O.A. therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 31, 214-225 (2011).
10. US Food and Drug Administration http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/020954s009s010lbl.pdf. Accessed 20 April 2012.
11. Lesko, L.J. et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J. Clin. Pharmacol. 43, 342-358 (2003).
12. Ginsburg, G.S. & Willard, H.F. Genomic and personalized medicine: foundations and applications. Transl. Res. 154, 277-287 (2009).
13. National Cancer Institute. targeted cancer therapies http://www.cancer. gov/cancertopics/factsheet/therapy/targeted. Accessed 21 April 2012.
14. US Food and Drug Administration. FDA seeks comment on proposed policy for diagnostic tests used with targeted drug therapies. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm262632.htm. Accessed 25 April 2012.
15. US Food and Drug Administration. table of Pharmacogenomic Biomarkers in Drug Labels http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/ucm083378.htm. Accessed 25 April 2012.
16. Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
17. Lesko, L.J. Personalized medicine: elusive dream or imminent reality? Clin. Pharmacol. Ther. 81, 807-816 (2007).
18. WarfarinDosing.org http://www.warfarindosing.org/Source/Home.aspx. Accessed 21 April 2012.
19. Dancey, J.E., Bedard, P.L., Onetto, N. & Hudson, T.J. the genetic basis for cancer treatment decisions. Cell 148, 409-420 (2012).
20. Temple, R. Enrichment of clinical study populations. Clin. Pharmacol. Ther. 88, 774-778 (2010).
21. Lesko, L.J., Zineh, I. & Huang, S.M. What is clinical utility and why should we care? Clin. Pharmacol. Ther. 88, 729-733 (2010).
22. Mega, J.L. et al. Dosing clopidogrel based on cYP2c19 genotype and the efect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306, 2221-2228 (2011).
23. Shuldiner, A.R. et al. Association of cytochrome P450 2c19 genotype with the antiplatelet efect and clinical efcacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
24. Leber, P.D. & Davis, C.S. threats to the validity of clinical trials employing enrichment strategies for sample selection. Control. Clin. Trials 19, 178-187 (1998).
25. Wagner, A.D., Grothe, W., Haerting, J., Kleber, G., Grothey, A. & Fileig, W.E. chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24, 2903-2909 (2006).
26. Shoupe, D. Individualizing hormone therapy to minimize risk. Women's Health 7, 475-485 (2011).
27. Epstein, R.S. et al. Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Efectiveness Study). J. Am. Coll. Cardiol. 55, 2804-2812 (2010).
28. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
29. Hamberg, A.K. et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in cYP2c9, VKORc1, and age. Clin. Pharmacol. Ther. 87, 727-734 (2010).
30. Danhof, M., De Jongh, J., De Lange, E.C., Della Pasqua, O., Ploeger, B.A. & Voskuyl, R.A. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47, 357-400 (2007).
31. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).
32. Edginton, A.N. & Willmann, S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin. Pharmacokinet. 47, 743-752 (2008).
33. Johnson, T.N., Boussery, K., Rowland-Yeo, K., Tucker, G.T. & Rostami-Hodjegan, A. A semi-mechanistic model to predict the efects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 49, 189-206 (2010).
34. Rowland, M., Peck, C. & Tucker, G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45-73 (2011).
35. European Medicines Agency committee for Medicinal Products for Human Use (cHMP). 2005. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function http://www. emea.europa.eu/pdfs/human/ewp/233902en.pdf. Accessed 25 April 2012.
36. Yang, J., Kjellsson, M., Rostami-Hodjegan, A. & Tucker, G.T. the efects of dose staggering on metabolic drug-drug interactions. Eur. J. Pharm. Sci. 20, 223-232 (2003).
37. Zhao, P. et al. Quantitative evaluation of pharmacokinetic inhibition of cYP3A substrates by ketoconazole: a simulation study. J. Clin. Pharmacol. 49, 351-359 (2009).
38. the cDER Science Prioritization and Review committee (SPaRc). Identifying cDER's Science and Research Needs Report http://www.fda.gov/downloads/drugs/ scienceresearch/ucm264594.pdf. Accessed 20 April 2012.
39. US Food and Drug Administration. center for Drug Evaluation and Research (cDER) and center for Biologics Evaluation and Research (cBER). Guidance for Industry: Population Pharmacokinetics http://www.fda.gov/downloads/ ScienceResearch/Specialtopics/WomensHealthResearch/UcM133184.pdf. Accessed 20 April 2012.
40. US Food and Drug Administration. center for Drug Evaluation and Research (cDER) and center for Biologics Evaluation and Research (cBER). Guidance for Industry: Exposure-Response Relationships\Study Design, Data Analysis, and Regulatory Applications http://www.fda.gov/downloads/Drugs/ GuidancecomplianceRegulatoryInformation/Guidances/ucm072109.pdf. Accessed 20 April 2012.
41. US Food and Drug Administration. Sortable listing of clinical Pharmacology Guidances http://www.fda.gov/Drugs/Guidance complianceRegulatoryInformation/Guidances/ucm064982.htm. Accessed 20 April 2012.
42. Lesko, L.J. & Zineh, I. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics 11, 507-512 (2010).
43. US Food and Drug Administration. Drugs: Genomics http://www.fda.gov/ Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/default.htm. Accessed 20 April 2012.
44. Topol, E. The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care. (Basic Books, Perseus Books Group, New York, 2012).
45. andMe. Parkinson's Disease https://www.23andme.com/pd/. Accessed 21 April 2012.
46. National Parkinson Foundation. 23andMe http://www.parkinson. org/Parkinson-s-Disease/treatment/Experimental-therapy-clinical-trials/23andMe. aspx. Accessed 21 April 2012.
47. Parsa, A. et al. Autologous heat shock protein vaccine (HSPPc-96) for patients with recurrent glioblastoma (GBM): results of a Phase 2 multicenter clinical trial with immunological assessments. Abstract http://abstract.asco. org/AbstView-102-85010.html, (2011). Accessed 21 April 2012.
48. Highlights of Prescribing Information http://www.provenge.com/pdf/ prescribing-information.pdf. Accessed 25 April 2012.
49. Booth, C. & Gaspar, H.B. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodefciency (ScID). Biologics 3, 349-358 (2009).
50. Nicholson, J.K. & Lindon, J.C. Systems biology: Metabonomics. Nature 455, 1054-1056 (2008).
51. Hall, S.S. Diseases in a dish. Sci. Am. 304, 40-45 (2011).
52. Jiang, H. et al. Parkinson controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat. Commun. (7 February 2012).
53. Chen, R. et al. Personal omics profling reveals dynamic molecular and medical phenotypes. Cell 148, 1293-1307 (2012).